PMC:7408073 / 100966-101487 JSONTXT

{"project":"LitCovid-PD-FMA-UBERON","denotations":[{"id":"T6","span":{"begin":96,"end":100},"obj":"Body_part"},{"id":"T7","span":{"begin":257,"end":261},"obj":"Body_part"},{"id":"T8","span":{"begin":329,"end":346},"obj":"Body_part"}],"attributes":[{"id":"A6","pred":"fma_id","subj":"T6","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A7","pred":"fma_id","subj":"T7","obj":"http://purl.org/sig/ont/fma/fma7195"},{"id":"A8","pred":"fma_id","subj":"T8","obj":"http://purl.org/sig/ont/fma/fma265130"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"LitCovid-PD-UBERON","denotations":[{"id":"T197","span":{"begin":96,"end":100},"obj":"Body_part"},{"id":"T198","span":{"begin":257,"end":261},"obj":"Body_part"},{"id":"T199","span":{"begin":329,"end":346},"obj":"Body_part"}],"attributes":[{"id":"A197","pred":"uberon_id","subj":"T197","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A198","pred":"uberon_id","subj":"T198","obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"A199","pred":"uberon_id","subj":"T199","obj":"http://purl.obolibrary.org/obo/UBERON_0000065"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"LitCovid-PubTator","denotations":[{"id":"3490","span":{"begin":237,"end":241},"obj":"Gene"},{"id":"3491","span":{"begin":462,"end":465},"obj":"Gene"},{"id":"3492","span":{"begin":9,"end":12},"obj":"Gene"},{"id":"3493","span":{"begin":110,"end":114},"obj":"Species"},{"id":"3494","span":{"begin":118,"end":129},"obj":"Species"},{"id":"3495","span":{"begin":96,"end":109},"obj":"Disease"},{"id":"3496","span":{"begin":257,"end":274},"obj":"Disease"},{"id":"3497","span":{"begin":449,"end":457},"obj":"Disease"}],"attributes":[{"id":"A3490","pred":"tao:has_database_id","subj":"3490","obj":"Gene:59272"},{"id":"A3491","pred":"tao:has_database_id","subj":"3491","obj":"Gene:4295"},{"id":"A3492","pred":"tao:has_database_id","subj":"3492","obj":"Gene:69563"},{"id":"A3493","pred":"tao:has_database_id","subj":"3493","obj":"Tax:10090"},{"id":"A3494","pred":"tao:has_database_id","subj":"3494","obj":"Tax:287"},{"id":"A3495","pred":"tao:has_database_id","subj":"3495","obj":"MESH:D012141"},{"id":"A3496","pred":"tao:has_database_id","subj":"3496","obj":"MESH:D011014"},{"id":"A3497","pred":"tao:has_database_id","subj":"3497","obj":"MESH:D064420"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"LitCovid-PD-MONDO","denotations":[{"id":"T559","span":{"begin":262,"end":274},"obj":"Disease"},{"id":"T560","span":{"begin":353,"end":357},"obj":"Disease"}],"attributes":[{"id":"A559","pred":"mondo_id","subj":"T559","obj":"http://purl.obolibrary.org/obo/MONDO_0021166"},{"id":"A560","pred":"mondo_id","subj":"T560","obj":"http://purl.obolibrary.org/obo/MONDO_0005091"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T10","span":{"begin":96,"end":100},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T11","span":{"begin":96,"end":100},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"},{"id":"T12","span":{"begin":130,"end":138},"obj":"http://purl.obolibrary.org/obo/NCBITaxon_2"},{"id":"T13","span":{"begin":257,"end":261},"obj":"http://purl.obolibrary.org/obo/UBERON_0002048"},{"id":"T14","span":{"begin":257,"end":261},"obj":"http://www.ebi.ac.uk/efo/EFO_0000934"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T58611","span":{"begin":226,"end":235},"obj":"Chemical"}],"attributes":[{"id":"A31868","pred":"chebi_id","subj":"T58611","obj":"http://purl.obolibrary.org/obo/CHEBI_25367"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T2","span":{"begin":262,"end":274},"obj":"http://purl.obolibrary.org/obo/GO_0006954"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"LitCovid-sentences","denotations":[{"id":"T492","span":{"begin":146,"end":287},"obj":"Sentence"},{"id":"T493","span":{"begin":288,"end":521},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}

{"project":"2_test","denotations":[{"id":"32708755-31645418-20679035","span":{"begin":140,"end":143},"obj":"31645418"}],"text":"Finally, MLN-4760 was also administered (2.5 mg/kg per day) by nasal inhalation for 2–3 days in lung-infected mice by Pseudomonas bacteria [185]. Interestingly, the report underscores the role played by local concentration of molecules (ACE2) in modulating lung inflammation and disease. For these reasons, in diseases involving respiratory tract, like SARS, inhalation treatment is preferable, even for the lower concentration (and hopefully lower toxicity) of MLN-4760 needed for this route of treatment administration."}